DIA Share Price Performance
€75.98
-24.52 (-24.40%)
17.9% undervalued intrinsic discount
€92.50
Fair Value
Price €75.98
AnalystConsensusTarget €92.50
AnalystHighTarget €105.00
AnalystLowTarget €58.00
Fair Value€92.50
Share Pricen/a
DiaSorin S.p.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
DIA Community Narratives
AN
Fair Value €92.5 17.9% undervalued intrinsic discount
North American Hospital Expansion Will Advance Diagnostic Opportunities
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value €105 27.6% undervalued intrinsic discount
Evolving Diagnostics Platforms Will Revolutionize Patient Care Worldwide
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value €58 31.0% overvalued intrinsic discount
Global Pricing Pressures Will Erode Margins Despite Cost Cuts
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Evolving Diagnostics Platforms Will Revolutionize Patient Care Worldwide
Key Takeaways Expansion in the U.S. hospital market and innovative diagnostics could drive revenue and earnings growth well above current analyst expectations. Manufacturing efficiencies and investments in automation and connectivity may fuel margin expansion and strengthen the company's advantage in both institutional and near-patient settings.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€105
27.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
8.97% p.a.
Profit Margin
20.51%
Future PE
23.97x
Price in 2029
€142.65
Global Pricing Pressures Will Erode Margins Despite Cost Cuts
Key Takeaways Intensifying global cost controls and market shifts toward point-of-care testing are compressing DiaSorin's pricing power, margins, and weakening its traditional product demand. Heightened regulatory and compliance pressures, along with currency and macro volatility, are threatening innovation cycles and adding instability to international earnings.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€58
31.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
5.15% p.a.
Profit Margin
18.12%
Future PE
16.71x
Price in 2028
€78.67
North American Hospital Expansion Will Advance Diagnostic Opportunities
Key Takeaways Expansion in North America and emerging markets, along with new specialty diagnostics, supports sustained revenue growth and improved profitability from widening healthcare demand. Manufacturing optimization and innovative test development drive operational efficiencies, premium pricing, and strengthened margins amid ongoing industry price pressures.Read more
63
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
€92.5
17.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
7.08% p.a.
Profit Margin
19.38%
Future PE
23.62x
Price in 2028
€125.67
Trending Discussion
Recently Updated Narratives
AN
DIA: Reset Expectations Will Support Medium Term Execution-Driven Upside Potential
Fair Value: €105 27.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DIA: Execution And Margin Pressures Will Shape A More Muted Outlook
Fair Value: €58 31.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DIA: Medium Term Upside Will Persist Despite Near Term Market Caution
Fair Value: €92.5 17.9% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DiaSorin S.p.A. Key Details
About DIA
- Founded
- 1968
- Employees
- 3280
- CEO
- WebsiteView website
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
